<DOC>
	<DOC>NCT01247961</DOC>
	<brief_summary>This pilot trial will evaluate the following in patients with acute pancreatitis: 1. Safety profile of early treatment with intravenous dexamethasone 2. Impact of dexamethasone on systemic inflammation in patients with acute pancreatitis 3. Provide preliminary data on potential impact of early treatment with steroids on clinical outcomes</brief_summary>
	<brief_title>Early Treatment With Dexamethasone in Mild Acute Pancreatitis</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age&gt;=18 years Diagnosis of acute pancreatitis confirmed by at least 2 of the following: 1. Typical epigastric abdominal pain 2. Elevation amylase/lipase &gt;3 times upper limit normal and/or 3. Confirmatory findings on crosssectional imaging Enrollment within 8 hours of presentation Class II or greater NYHA heart failure Oxygen dependent COPD Chronic kidney disease&gt;stage 2 Cirrhosis Existing necrosis on abdominal CT Organ dysfunction prior to enrollment Sepsis Acute respiratory distress syndrome Malignancy not in remission for at least 5 years Active drug use Known allergy to dexamethasone Altered mental status Insulinrequiring diabetes Abdominal surgery within 60 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>